OrgaNext Research

OrgaNext Research is a clinical-stage biotechnology company focused on developing therapeutic solutions for muscle wasting and frailty in the elderly. Based in the Netherlands, the company addresses the significant unmet need in sarcopenia, a condition involving the loss of muscle mass and strength that leads to decreased mobility and independence. Their lead candidate, ORG-101, is a combination therapy that pairs a pharmacological agent with nutritional support and exercise to maximize functional recovery. OrgaNext's approach emphasizes a holistic treatment model to improve the quality of life for geriatric patients. The company collaborates closely with academic institutions and clinical experts to validate its multi-modal treatment strategies.